Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine

Neuropsychopharmacology. 2024 Jan;49(1):315-316. doi: 10.1038/s41386-023-01652-x.

Marjorie R Levinstein¹, Michael Michaelides^{2

3}

¹ Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 21224, USA. Marjorie.levinstein@nih.gov.
² Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 21224, USA. Mike.michaelides@nih.gov.
³ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Mike.michaelides@nih.gov.

No abstract available

Publication types